Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Continuous C-peptide loss in patients with type 1 diabetes and multiethnic background.

Dantas JR, Almeida MH, Barone B, Serfaty F, Raggio LR, Kupfer R, Zajdenverg L, Oliveira JE, Rodacki M.

Diabetes Res Clin Pract. 2013 Mar;99(3):e33-6. doi: 10.1016/j.diabres.2012.12.019. Epub 2013 Jan 21.

PMID:
23347689
2.

[Pancreatic function assessment in type 1 diabetes mellitus patients according to disease duration].

Dantas JR, Almeida MH, Barone B, Campos F, Kupfer R, Milech A, Zajdenverg L, Rodacki M, Oliveira JE.

Arq Bras Endocrinol Metabol. 2009 Feb;53(1):64-71. Portuguese.

3.

[Factors involved in ketoacidosis at the onset of type 1 diabetes in childhood].

Młynarski W, Zmysłowska A, Kubryn I, Perenc M, Bodalski J.

Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2003;9(1):23-8. Polish.

PMID:
12831634
4.

[Factors affecting C-peptide level during the first year of type 1 diabetes in children].

Zmysłowska A, Szadkowska A, Andrzejewski W, Wegner O, Wyka K, Młynarski W, Bodalski J.

Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2004;10(2):103-11. Polish.

PMID:
15504313
5.

Fulminant type 1 diabetes mellitus in Korean adolescents.

Kim MS, Kim CJ, Ko CW, Hwang PH, Lee DY.

J Pediatr Endocrinol Metab. 2011;24(9-10):679-81.

PMID:
22145456
6.

High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry.

Decochez K, Tits J, Coolens JL, Van Gaal L, Krzentowski G, Winnock F, Anckaert E, Weets I, Pipeleers DG, Gorus FK.

Diabetes Care. 2000 Jun;23(6):838-44.

7.

Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds.

Almeida MH, Dantas JR, Barone B, Serfaty FM, Kupfer R, Albernaz M, Bencke MR, Zajdenverg L, Rodacki M, Oliveira JE.

Clinics (Sao Paulo). 2013 Jan;68(1):123-6.

8.

Proinsulin/C-peptide ratio, glucagon and remission in new-onset Type 1 diabetes mellitus in young adults.

Schölin A, Nyström L, Arnqvist H, Bolinder J, Björk E, Berne C, Karlsson FA; Diabetes Incidence Study Group in Sweden (DISS).

Diabet Med. 2011 Feb;28(2):156-61. doi: 10.1111/j.1464-5491.2010.03191.x.

PMID:
21219422
9.

Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis.

Mortensen HB, Swift PG, Holl RW, Hougaard P, Hansen L, Bjoerndalen H, de Beaufort CE, Knip M; Hvidoere Study Group on Childhood Diabetes.

Pediatr Diabetes. 2010 Jun;11(4):218-26. doi: 10.1111/j.1399-5448.2009.00566.x. Epub 2008 Aug 25.

PMID:
19708904
10.

Characteristics of Caucasian type 2 diabetic patients during ketoacidosis and at follow-up.

Pitteloud N, Philippe J.

Schweiz Med Wochenschr. 2000 Apr 22;130(16):576-82.

PMID:
10842773
11.

Sensor augmented pump therapy from onset of type 1 diabetes: late follow-up results of the Pediatric Onset Study.

Kordonouri O, Hartmann R, Pankowska E, Rami B, Kapellen T, Coutant R, Lange K, Danne T.

Pediatr Diabetes. 2012 Nov;13(7):515-8. doi: 10.1111/j.1399-5448.2012.00863.x. Epub 2012 Apr 5.

PMID:
22487079
12.

Race-related differences in metabolic control among adults with diabetes.

Summerson JH, Konen JC, Dignan MB.

South Med J. 1992 Oct;85(10):953-6.

PMID:
1411733
13.

GADA and islet cell antibodies in Romanian children and adolescents with diabetes mellitus.

Serban V, Enache A, Vlad A, Sima A, Roşu M, Roşca A, Drăghici C.

Rom J Intern Med. 2004;42(2):325-32.

PMID:
15529623
14.

Clinical characteristics, GAD antibody (GADA) and change of C-peptide in Korean young age of onset diabetic patients.

Ahn CW, Kim HS, Nam JH, Song YD, Lim SK, Kim KR, Lee HC, Huh KB.

Diabet Med. 2002 Mar;19(3):227-33.

PMID:
11918625
15.

Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.

Schloot NC, Meierhoff G, Lengyel C, Vándorfi G, Takács J, Pánczél P, Barkai L, Madácsy L, Oroszlán T, Kovács P, Sütö G, Battelino T, Hosszufalusi N, Jermendy G.

Diabetes Metab Res Rev. 2007 May;23(4):276-85.

PMID:
17103487
16.
17.

Glutamic acid decarboxylase and ICA512/IA-2 autoantibodies as disease markers and relationship to residual beta-cell function and glycemic control in young type 1 diabetic patients.

Zanone MM, Catalfamo E, Pietropaolo SL, Rabbone I, Sacchetti C, Cerutti F, Trucco M, Cavallo-Perin P.

Metabolism. 2003 Jan;52(1):25-9.

PMID:
12524658
18.

Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents.

Ludvigsson J, Carlsson A, Deli A, Forsander G, Ivarsson SA, Kockum I, Lindblad B, Marcus C, Lernmark Å, Samuelsson U.

Diabetes Res Clin Pract. 2013 May;100(2):203-9. doi: 10.1016/j.diabres.2013.03.003. Epub 2013 Mar 22.

PMID:
23529064
19.

Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes.

Picardi A, Visalli N, Lauria A, Suraci C, Buzzetti R, Merola MK, Manfrini S, Guglielmi C, Gentilucci UV, Pitocco D, Crinò A, Bizzarri C, Cappa M, Pozzilli P.

Horm Metab Res. 2006 Oct;38(10):668-72.

PMID:
17075776
20.

Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus.

Sjöberg S, Gunnarsson R, Gjötterberg M, Lefvert AK, Persson A, Ostman J.

Diabetologia. 1987 Apr;30(4):208-13.

PMID:
3297896

Supplemental Content

Support Center